O’Sullivan CC, Moon DH, Kohn EC, Lee JM (2014) Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors. Front Oncol 4:42. https://doi.org/10.3389/fonc.2014.00042

Article  PubMed  PubMed Central  Google Scholar 

Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J, de Murcia G (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277(25):23028–23036

Article  CAS  PubMed  Google Scholar 

Memisoglu A, Samson L (2000) Base excision repair in yeast and mammals. Mutat Res 451(1–2):39–51

Article  CAS  PubMed  Google Scholar 

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917

Article  CAS  PubMed  Google Scholar 

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921

Article  CAS  PubMed  Google Scholar 

Iglehart JD, Silver DP (2009) Synthetic lethality–a new direction in cancer-drug development. N Engl J Med 361(2):189–191

Article  CAS  PubMed  Google Scholar 

Lord CJ, Ashworth A (2017) PARP inhibitors: synthetic lethality in the clinic. Science 355(6330):1152–1158. https://doi.org/10.1126/science.aam7344

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helleday T (2011) The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 5(4):387–393. https://doi.org/10.1016/j.molonc.2011.07.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72(21):5588–5599. https://doi.org/10.1158/0008-5472.CAN-12-2753

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim G, Ison G, McKee AE, Zhang H, Tang S, Gwise T, Sridhara R, Lee E, Tzou A, Philip R, Chiu HJ, Ricks TK, Palmby T, Russell AM, Ladouceur G, Pfuma E, Li H, Zhao L, Liu Q, Venugopal R, Ibrahim A, Pazdur R (2015) FDA approval summary: olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 21(19):4257–4261. https://doi.org/10.1158/1078-0432.Ccr-15-0887

Article  CAS  PubMed  Google Scholar 

Slade D (2020) PARP and PARG inhibitors in cancer treatment. Genes Dev 34(5–6):360–394. https://doi.org/10.1101/gad.334516.119

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balasubramaniam S, Beaver JA, Horton S, Fernandes LL, Tang S, Horne HN, Liu J, Liu C, Schrieber SJ, Yu J, Song P, Pierce W, Robertson KJ, Palmby TR, Chiu HJ, Lee EY, Philip R, Schuck R, Charlab R, Banerjee A, Chen XH, Wang X, Goldberg KB, Sridhara R, Kim G, Pazdur R (2017) FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin Cancer Res 23(23):7165–7170. https://doi.org/10.1158/1078-0432.Ccr-17-1337

Article  CAS  PubMed  Google Scholar 

Anscher MS, Chang E, Gao X, Gong Y, Weinstock C, Bloomquist E, Adeniyi O, Charlab R, Zimmerman S, Serlemitsos-Day M, Ning YM, Mayrosh R, Fuller B, Trentacosti AM, Gallagher P, Bijwaard K, Philip R, Ghosh S, Fahnbulleh F, Diggs F, Arora S, Goldberg KB, Tang S, Amiri-Kordestani L, Pazdur R, Ibrahim A, Beaver JA (2021) FDA approval summary: rucaparib for the treatment of patients with deleterious BRCA-Mutated metastatic castrate-resistant prostate cancer. Oncologist 26(2):139–146. https://doi.org/10.1002/onco.13585

Article  CAS  PubMed  Google Scholar 

Sisay M, Edessa D (2017) PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecol Oncol Res Pract 4:18. https://doi.org/10.1186/s40661-017-0055-8

Article  PubMed  PubMed Central  Google Scholar 

George RR, Thomas R, Davice A, Mathew MS (2022) Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract 28(4):924–934. https://doi.org/10.1177/10781552221073990

Article  CAS  PubMed  Google Scholar 

Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(10):1269–1282. https://doi.org/10.1016/s1470-2045(20)30447-2

Article  CAS  PubMed  Google Scholar 

Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A (2013) BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19(18):5003–5015. https://doi.org/10.1158/1078-0432.CCR-13-1391

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andrei AZ, Hall A, Smith AL, Bascunana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G (2015) Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Lett 364(1):8–16. https://doi.org/10.1016/j.canlet.2015.04.003

Article  CAS  PubMed  Google Scholar 

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E (2015) PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget 6(41):43978–43991. https://doi.org/10.18632/oncotarget.6287

Article  PubMed  PubMed Central  Google Scholar 

Wang B, Chu D, Feng Y, Shen Y, Aoyagi-Scharber M, Post LE (2016) Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-te trahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem 59(1):335–357. https://doi.org/10.1021/acs.jmedchem.5b01498

Article  CAS  PubMed  Google Scholar 

Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y (2014) Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2):433–443. https://doi.org/10.1158/1535-7163.MCT-13-0803

Article  CAS  PubMed  Google Scholar 

Mittra A, Doroshow JH, Chen AP (2021) BRCA Mutation and PARP Inhibitors. In: Handbook of Therapeutic Biomarkers in Cancer. Jenny Stanford Publishing, pp 533–575

de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA (2017) Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 7(6):620–629. https://doi.org/10.1158/2159-8290.CD-16-1250

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hobbs EA, Litton JK, Yap TA (2021) Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother 22(14):1825–1837. https://doi.org/10.1080/14656566.2021.1952181

Article  CAS  PubMed  PubMed Central  Google Scholar 

Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmana J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, Group AS (2019) A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO). Clin Cancer Res 25(9):2717–2724. https://doi.org/10.1158/1078-0432.CCR-18-1891

Article  CAS  PubMed  Google Scholar 

Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753–763. https://doi.org/10.1056/NEJMoa1802905

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH (2012) Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res 18(6):1655–1662. https://doi.org/10.1158/1078-0432.CCR-11-2890

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS (2013) Appraising iniparib, the PARP inhibitor that never was–what must we learn? Nat Rev Clin Oncol 10(12):688–696. https://doi.org/10.1038/nrclinonc.2013.177

Article  CAS  PubMed  Google Scholar 

Wilsker DF, Barrett AM, Dull AB, Lawrence SM, Hollingshead MG, Chen A, Kummar S, Parchment RE, Doroshow JH, Kinders RJ (2019) Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clin Cancer Res 25(10):3084–3095. https://doi.org/10.1158/1078-0432.CCR-18-2523

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoy SM (2018) Talazoparib: first global approval. Drugs 78(18):1939–1946.